Real-World Disease Burden and Healthcare Resource Utilization Among Patients with COPD and Asthma Using Triple Therapy (FF/UMEC/VI) in the United States

Purpose: Chronic obstructive pulmonary disease (COPD) and asthma are associated with chronic inflammation of the respiratory tract; despite some overlap of symptoms, they are considered separate disorders. Triple therapy is recommended for patients with COPD and asthma whose symptoms remain uncontrolled despite dual therapy. There are limited real -world studies evaluating outcomes among patients with COPD and asthma who are receiving inhaled triple therapy. This United States (US) -based realworld study aimed to evaluate clinical and economic outcomes among patients with COPD and asthma receiving single -inhaler triple therapy (fluticasone furoate/umeclidinium/vilanterol [FF/UMEC/VI]). Patients and Methods: Retrospective pre -post study using claims data from the Optum Clinformatics (R) database. Patients with COPD and asthma were indexed on the first date of FF/UMEC/VI prescription (1 October 2017-31 March 2019). Each patient acted as their own control. Patients were required to have continuous health plan enrollment for 12 months prior to (pre-treatment) and following (post -treatment) index. Exacerbations, all -cause and COPD-related healthcare resource utilization, and costs were compared before and after FF/UMEC/VI initiation. Results: Overall, 2743 patients were included (mean age: 71 years; 64% female). Cardiovascular disease was the most prevalent comorbidity during both the preand post -treatment periods (90% for both periods). There was a lower proportion of patients with >= 1 COPD exacerbation or >= 1 asthma exacerbation post -treatment versus pre-treatment (51% vs 57%, p<0.0001, and 22% vs 32%, p<0.0001, respectively). Fewer patients had >= 1 all -cause office visit post -treatment versus pre-treatment (99.3% vs 99.7%, p=0.0329); more patients had >= 1 COPD-related office visit post -treatment versus pre-treatment (89.6% vs 87.5%, p=0.0035). Total all -cause healthcare costs were significantly higher post -treatment versus pre-treatment ($72,809 vs $63,734, p<0.0001). The driver of increased costs appeared to be primarily non-COPD-related (COPD-related costs: post -treatment $27,779 vs pretreatment $25,081, p=0.0062). Conclusion: FF/UMEC/VI reduced exacerbations among patients with COPD and asthma in a real -world setting in the US.